17.14

0.41% -0.10

Hims Hers Health Inc (HIMS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HIMS? Forum Prognose

Schlusskurs vom Vortag:

$17.24

Offen:

$17.52

24-Stunden-Volumen:

20.40M

Relative Volume:

0.97

Marktkapitalisierung:

$3.91B

Einnahmen:

$1.78B

Nettoeinkommen (Verlust:

$164.40M

KGV:

24.84

EPS:

0.69

Netto-Cashflow:

$236.51M

1W Leistung:

-29.63%

1M Leistung:

-45.82%

6M Leistung:

-65.65%

1J Leistung:

-60.60%

1-Tages-Spanne:

$16.70

$17.63

1-Wochen-Bereich:

$16.35

$27.77

52-Wochen-Spanne:

$16.35

$72.98

Hims Hers Health Inc Stock (HIMS) Company Profile

Firmenname

Hims Hers Health Inc

Sektor

Healthcare (1115)

Branche

Drug Manufacturers - Specialty & Generic (85)

Telefon

415-851-0195

Adresse

2269 CHESTNUT ST, SAN FRANCISCO

Mitarbeiter

1,637

Twitter

Nächster Verdiensttermin

2025-02-24

Neueste SEC-Einreichungen

HIMS's Discussions on Twitter

Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HIMS Hims Hers Health Inc	17.16	3.92B	1.78B	164.40M	236.51M	0.69
TAK Takeda Pharmaceutical Co Adr	18.27	57.18B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	129.02	56.47B	9.40B	2.65B	2.24B	5.935
HLN Haleon Plc Adr	11.18	49.16B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	34.45	40.03B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	470.41	20.37B	3.13B	1.27B	1.12B	26.39

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-12	Eingeleitet	Evercore ISI	In-line
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-21	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2025-06-23	Herabstufung	Needham	Buy → Hold
2025-06-04	Bestätigt	Needham	Buy
2025-04-29	Herabstufung	TD Cowen	Buy → Hold
2025-02-18	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-01-10	Herabstufung	Citigroup	Neutral → Sell
2025-01-07	Eingeleitet	BTIG Research	Buy
2024-12-17	Eingeleitet	Morgan Stanley	Overweight
2024-11-14	Herabstufung	BofA Securities	Buy → Underperform
2024-08-22	Eingeleitet	Needham	Buy
2024-08-09	Herabstufung	Imperial Capital	Outperform → In-line
2024-05-22	Herabstufung	Citigroup	Buy → Neutral
2024-04-16	Herabstufung	Jefferies	Buy → Hold
2024-04-10	Eingeleitet	Canaccord Genuity	Buy
2024-02-28	Hochstufung	Imperial Capital	In-line → Outperform
2024-02-26	Eingeleitet	Leerink Partners	Market Perform
2023-12-07	Eingeleitet	Imperial Capital	In-line
2023-07-28	Eingeleitet	TD Cowen	Outperform
2023-04-11	Eingeleitet	Robert W. Baird	Neutral
2023-02-09	Hochstufung	Jefferies	Hold → Buy
2022-11-08	Hochstufung	BofA Securities	Neutral → Buy
2022-11-08	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-10-17	Herabstufung	Piper Sandler	Overweight → Neutral
2022-09-07	Eingeleitet	Truist	Hold
2022-07-15	Eingeleitet	SVB Leerink	Underperform
2022-04-14	Eingeleitet	Guggenheim	Buy
2022-04-01	Fortgesetzt	Credit Suisse	Outperform
2022-03-10	Eingeleitet	Deutsche Bank	Hold
2021-12-02	Eingeleitet	Jefferies	Hold
2021-11-11	Hochstufung	Piper Sandler	Neutral → Overweight
2021-07-06	Eingeleitet	BofA Securities	Neutral
2021-05-20	Hochstufung	Credit Suisse	Neutral → Outperform
2021-04-21	Eingeleitet	Truist	Hold
2021-03-09	Eingeleitet	Credit Suisse	Neutral
2021-03-02	Hochstufung	Citigroup	Neutral → Buy
2021-02-17	Eingeleitet	Citigroup	Neutral
2021-02-12	Eingeleitet	Piper Sandler	Neutral
2021-02-08	Eingeleitet	Tigress Financial	Buy

Alle ansehen

Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten

10:24 AM

HIMS Selloff Creates De-Risked Entry (NYSE:HIMS) - Seeking Alpha

10:24 AM

08:56 AM

Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning - AOL.com

08:56 AM

06:29 AM

Pharmaceutical industry spends more on ads in the US despite stricter FDA guidelines - medwatch.com

06:29 AM

05:28 AM

The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 46% - simplywall.st

05:28 AM

04:52 AM

Novo’s GLP-1 Patent Suit Against Hims Takes Aim at Compounding - Bloomberg Law News

04:52 AM

04:37 AM

Hims is in the crosshairs. Is a crackdown coming for compounding? - statnews.com

04:37 AM

03:30 AM

HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? - Stocktwits

03:30 AM

02:17 AM

Deutsche Bank Maintains Hold on HIMS (Hims & Hers) Feb 10, 2026 - Meyka

02:17 AM

Feb 10, 2026

'Health risk': Novo Nordisk sues Hims & Hers over cheaper version of Ozempic, Wegovy fat loss pills - MSN

Feb 10, 2026

Stocks making big moves yesterday: Shopify, Snowflake, Ryan Specialty, Merchants Bancorp, and Hims & Hers Health - The Globe and Mail

Feb 10, 2026

Novo Nordisk Files Patent Lawsuit Against Hims & Hers Over Compounded Semaglutide Products - Law Commentary

Feb 10, 2026

Fight over GLP-1 alternatives escalates as Novo Nordisk sues Hims & Hers - Axios

Feb 10, 2026

Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’ - The Hill

Feb 10, 2026

Decoding Hims & Hers Health's Options Activity: What's the Big Picture? - Benzinga

Feb 10, 2026

Palmetto Grain Brokerage - Palmetto Grain Brokerage

Feb 10, 2026

As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock? - Yahoo Finance

Feb 10, 2026

Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha

Feb 10, 2026

The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS) - FinancialContent

Feb 10, 2026

Deutsche Bank Cuts Price Target on Hims & Hers Health to $31 From $42, Keeps Hold Rating - marketscreener.com

Feb 10, 2026

Novo Nordisk, maker of Ozempic, sues over weight loss drug copycats - NewsNation

Feb 10, 2026

Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans - Yahoo Finance

Feb 10, 2026